Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solifenacin for Ureteral Stent-induced Pain and LUTS
NCT01381120Phase 4Completed
- Sponsor
- Barrie Urology Associates
- Start
- Oct 2010
- Primary completion
- Jun 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of solifenacin in ureteral stent-related pain (USRP) and lower urinary tract symptoms (LUTS) (2 arms), sponsored by Barrie Urology Associates. Primary endpoint: Change in Post-ureteroscopy Stent-induced Pain at 3 months. Started Oct 2010; status: completed.
02
Drugs
solifenacin
03
Conditions
ureteral stent-related pain (USRP)lower urinary tract symptoms (LUTS)
Beyond the preview
Go deeper on NCT01381120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381120.